A Multicenter, Retrospective Observational Study to Evaluate the Effectiveness and Safety of Polatuzumab Vedotin
- Conditions
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Interventions
- Registration Number
- NCT04624893
- Lead Sponsor
- Jiangsu Cancer Institute & Hospital
- Brief Summary
To assess the clinical outcomes following treatment with Pola in combination with Bendamustine, Rituximab (BR) or Rituximab (R) in patients with R/R DLBCL who are not eligible for transplantation in the real-world setting.
- Detailed Description
This study is a multi-center retrospective observational study. It aims to evaluate the effectiveness and safety of polatuzumab vedotin treatment in patients with hematopoietic stem cell transplantation ineligible relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), who met the criteria to access Pola through the compassionate use program (CUP). Based on the medical records of patients in the four participating hospitals, the study database will be established by using the unified case report form (CRF) to search extract information the data of target population from the hospital database, that is, the variables without personal identification information.
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 35
Hospitalized patients Patients who enrolled in the Pola CUP program and met the following criteria:
- Histologically confirmed DLBCL, patients have exhausted all therapeutic options for DLBCL and have been treated with at least two prior lines of therapy including R-CHOP (or similar regimen for 1L DLBCL)
- Not considered to be eligible for Bone Marrow Transplantation (BMT) (both allogenic or autologous)
- Have documented recent progression following or during last treatment, or became intolerant to the last treatment
- Does not have ≥ Grade 2 peripheral neuropathy(PN) prior to receiving Pola
- Patients treated with Pola-BR or Pola-R regimens
- Patients participating in other clinical studies of Pola.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Pola BR/R Polatuzumab Vedotin-Piiq Patients with R/R DLBCL who are enrolled in the Pola CUP program in China, and treated with Pola-BR or Pola-R regimens.
- Primary Outcome Measures
Name Time Method Investigator-assessed best overall response (BOR) From the start of the treatment until the date of first documented progression or the completion of the treatment(up to six cycles, each cycle is 21 days) Best overall response (BOR) assessed by the investigator, is based on either PET-CT or CT, and defined as the percentage of patients with CR or PR.
- Secondary Outcome Measures
Name Time Method Duration of response (DOR) From initial CR or PR to disease progression, relapse, or death from any cause, whichever occurred first, assessed up to 25 months DOR is defined as the time from initial complete response (CR) or partial response (PR) to disease progression, relapse, or death from any cause, whichever occurred first.
Progression free survival (PFS) From the start of treatment until disease progression, relapse, or death from any cause, whichever occurred first,assessed up to 30 months PFS is defined as the time from the start of treatment until disease progression, relapse, or death from any cause, whichever occurred first.
Objective response rate (ORR) At end of the treatment(up to six cycles, each cycle is 21 days) Objective response rate (ORR) assessed by the investigator at the end of treatment (EOT), is defined as the percentage of patients with CR or PR at the end of treatment.
Complete response (CR) At end of the treatment(up to six cycles, each cycle is 21 days) CR rate is defined as the percentage of patients with CR.
Trial Locations
- Locations (1)
Jiangsu Cancer Hospital
🇨🇳Nanjing, Jiangsu, China